Corcept Therapeutics (CORT) Other Accumulated Expenses (2010 - 2025)

Corcept Therapeutics has disclosed Other Accumulated Expenses across 14 years of filings, most recently posting $34.0 million for Q4 2025.

• Other Accumulated Expenses for Q4 2025 came in at $34.0 million, changed 0.25% year-over-year; the trailing twelve-month figure through Dec 2025 was $34.0 million (changed 0.25% YoY), and the FY2025 annual result was $34.0 million, changed 0.25% from the prior year.
• Other Accumulated Expenses came in at $34.0 million for Q4 2025 at Corcept Therapeutics, up from $28.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $34.0 million in Q4 2025 to a low of $12.4 million in Q4 2021.
• The 5-year median for Other Accumulated Expenses is $21.7 million (2023), against an average of $23.1 million.
• Across the five-year window, Other Accumulated Expenses jumped 58.78% in 2024 and climbed 0.25% in 2025, its largest moves.
• Corcept Therapeutics' Other Accumulated Expenses stood at $12.4 million in 2021, then rose by 17.13% to $14.6 million in 2022, then jumped by 46.37% to $21.3 million in 2023, then surged by 58.78% to $33.9 million in 2024, then rose by 0.25% to $34.0 million in 2025.
• The last three Other Accumulated Expenses figures came in at $34.0 million (Q4 2025), $28.3 million (Q3 2025), and $29.0 million (Q2 2025), per Business Quant data.